acebutolol has been researched along with Obesity, Morbid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Aczél, S; Bilz, S; Brändle, M; Frei, N; Räss, A; Schoeb, M | 1 |
| Abreu Padín, C; Castro Ramos, JC; Gómez Peralta, F; Gómez Rodríguez, S | 1 |
| Barish, C; Bregman, D; He, A; Malone, M | 1 |
1 review(s) available for acebutolol and Obesity, Morbid
| Article | Year |
|---|---|
Intravenous iron induced severe hypophophatemia in a gastric bypass patient.
Topics: Female; Ferric Compounds; Gastric Bypass; Humans; Hypophosphatemia; Iron Deficiencies; Maltose; Middle Aged; Obesity, Morbid; Postoperative Complications | 2019 |
2 other study(ies) available for acebutolol and Obesity, Morbid
| Article | Year |
|---|---|
High Risk of Hypophosphatemia in Patients with Previous Bariatric Surgery Receiving Ferric Carboxymaltose: A Prospective Cohort Study.
Topics: Adult; Aged; Anemia, Iron-Deficiency; Bariatric Surgery; Female; Ferric Compounds; Fibroblast Growth Factor-23; Humans; Hypophosphatemia; Maltose; Middle Aged; Obesity, Morbid; Prospective Studies; Young Adult | 2020 |
Comparative review of the safety and efficacy of ferric carboxymaltose versus standard medical care for the treatment of iron deficiency anemia in bariatric and gastric surgery patients.
Topics: Adult; Anemia, Iron-Deficiency; Bariatric Surgery; Biomarkers; Dietary Supplements; Dose-Response Relationship, Drug; Female; Ferric Compounds; Ferritins; Hematinics; Hemoglobins; Humans; Infusions, Intravenous; Iron, Dietary; Malabsorption Syndromes; Male; Maltose; Middle Aged; Obesity, Morbid; Parenteral Nutrition; Postoperative Complications; Randomized Controlled Trials as Topic; Retrospective Studies; Transferrin; Treatment Outcome; United States | 2013 |